Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 701–800 of 1,000
Xu, J., Chang, D., Chui, J. N., Cao, J., & Negus, J. J. (2022) · Journal of Orthopaedics · doi:10.1016/j.jor.2022.02.003 · Cited by 11
Combination of Superficial and Deep Blocks with Rivaroxaban
Chelly, J. E., Metais, B., Schilling, D., Luke, C., & Taormina, D. (2015) · Pain Medicine · doi:10.1111/pme.12801 · Cited by 10
Thrombin inhibitors: surgical considerations and pharmacology
Breik, O., Tadros, R., & Devitt, P. G. (2013) · ANZ Journal of Surgery · doi:10.1111/ans.12078 · Cited by 10
“Several largescale clinical trials have shown a lower incidence of venous thromboembolic events compared with enoxaparin in patients after total hip or total knee replacement.(2,3) These studies have demonstrated a slightly increased bleeding risk with rivaroxaban compared with enoxaparin.”
BackgroundConsenso SECOT sobre tromboembolismo en la cirugía protésica de rodilla y cadera
Castellet, E., Peidro, L., & Otero, R. (2013) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2013.01.003 · Cited by 12
Treatment of thromboembolism in cancer patients
Panova‐Noeva, M., & Falanga, A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.494181 · Cited by 11
“Major bleeding was rare in all four studies and not significantly different between the two arms [63-66].”
BackgroundLeReun, C., Wells, P., Diamantopoulos, A., Rasul, F., Lees, M., & Sengupta, N. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.564699 · Cited by 10
Pilge, H., Fröbel, J., Mrotzek, S. J., Fischer, J., Prodinger, P. M., Zilkens, C., Bittersohl, B., & Krauspe, R. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-0966-2 · Cited by 12
“With the use of Enoxaparin (a commonly used LMWH), the risk can be reduced to 2 % [3].”
Pharmacology of Antithrombotic Drugs
Haqqani, O. P., Iafrati, M. D., & Freedman, J. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2930-6.00007-0 · Cited by 14
Yu, Z. J., Shan, P., Yang, X., & Lou, X.-J. (2018) · Bioscience Reports · doi:10.1042/bsr20180423 · Cited by 10
Rahman, W. A., Habsa, G. H., Al-Mohrej, O. A., Hammad, M. A., Selim, N. M., & Hammad, A. (2020) · Journal of orthopaedic surgery · doi:10.1177/2309499020938865 · Cited by 10
Direct Oral Anticoagulants: A Review for the Non-Specialist
Gunawardena, T. (2021) · Hematology Reports · doi:10.4081/hr.2021.9239 · Cited by 10
Tanrıkulu, S., & Gönen, E. (2017) · Türk Ortopedi ve Travmatoloji Birliği Derneği · doi:10.14292/totbid.dergisi.2017.62 · Cited by 11
Huang, Z., Xu, X., Xu, D., Zhao, P., & Zou, M. (2023) · Medicine · doi:10.1097/md.0000000000032635 · Cited by 14
“…Sweden Dabigatran 65 ± 10 1146 (510/636) NA 1.42 ± 0.48 THA LMWH 64 ± 11 1154 (503/651) NA 1.45 ± 0.48 18 Eriksson 2007 Sweden Rivaroxaban 66 (32–84) 77 (32/45) 28 (18–38) NA THA LMWH 64 (30–92) 162 (74/88) 28 (19–44) NA 19 Eriksson 2007 Sweden Darexaban NA NA NA NA THA LMWH NA NA NA NA 20…”
InfluentialThrombembolic complications after total ankle replacement
Barg, A., Barg, K., Schneider, S. W., Pagenstert, G., Gloyer, M., Henninger, H. B., & Valderrábano, V. (2013) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-013-9186-7 · Cited by 11
“Rivaroxaban has been shown to be superior to enoxaparin for thromboprophylaxis after total knee [66] and total hip replacement [67] with similar rates of bleeding.”
BackgroundThromboprophylaxis in major knee and hip replacement surgery: a review
Gonzalo Eymin, L., & Jaffer, A. K. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0751-5 · Cited by 10
“In the first three RECORD studies, rivaroxaban was administered at a dose of 10 mg once daily and sc enoxaparin was administered at a dose of 40 mg once daily for a variety of durations [30, 33, 34].”
BackgroundMethodInfluentialAgnelli, G., & Bounameaux, H. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0627 · Cited by 10
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
Sherid, M., Sulaiman, S., Samo, S., Husein, H., Tupper, R. S., Spurr, C., Sifuentes, H., & Sridhar, S. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/9589036 · Cited by 11
“05%) in the enoxaparin group during the study period of 5 weeks for the thromboprophylaxis after hip arthroplasty [2].”
BackgroundBeyer‐Westendorf, J., Mouret, P., & Turpie, A. G. G. (2017) · Orthopedic Research and Reviews · doi:10.2147/orr.s105227 · Cited by 10
Zhang, C., Xu, B., Liang, G., Zeng, X., Chen, Y., Zhang, F., Wan, Z., Yu, W., Chen, D., Ge, Z., et al. (2018) · Journal of International Medical Research · doi:10.1177/0300060518762281 · Cited by 10
“Although fatal PE is rare after initial THA, and although some studies have shown that potent pharmacologic prophylaxis for venous thromboembolism does not decrease the rate of fatal PE after hip or knee arthroplasty, early detection and timely treatment are important in the management of this life-threatening complic…”
ResultVitamin K antagonists: Ready to be replaced?
Lüscher, T. F., & Steffel, J. (2012) · Hämostaseologie · doi:10.5482/ha-12050008 · Cited by 11
Ahuja, T., Raco, V., Papadopoulos, J., & Green, D. (2021) · PubMed · doi:10.1097/pts.0000000000000535 · Cited by 13
Denas, G., & Pengo, V. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.527947 · Cited by 9
“Phase II studies have shown that daily doses of rivaroxaban 5 -- 20 mg have similar efficacy and safety as compared to enoxaparin in the prevention of VTE after orthopedic surgery; however, 10 mg once daily dose had a favorable combination of efficacy and safety [77,78] and was further evaluated in the RECORD trials […”
BackgroundNúñez, J. H., Borim, F. M., Escudero-Cisneros, B., Martínez-Peña, J., Bosch-García, D., Anglés, F., & Guerra-Farfán, E. (2023) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2024.01.024 · Cited by 9
Peidro-Garcés, L., Otero-Fernández, R., & Lozano-Lizarraga, L. (2012) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2012.10.009 · Cited by 10
Accidents hémorragiques des nouveaux anticoagulants oraux et examens de la coagulation
Samama, M. M., Conard, J., & Louët, A. L. (2013) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2013.05.005 · Cited by 9
“Elles proviennent d’études pharmacocinétiques et de nombreux essais cliniques (EINSTEIN [6], RECORD 1 [7], RECOVER [8], RE-LY [9], ROCKET [10]).”
BackgroundNew pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010
Armaganijan, L., Eikelboom, J. W., Healey, J. S., & Morillo, C. A. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0084-8 · Cited by 10
Kasina, P., Wall, A., Lapidus, L. J., Rolfson, O., Kärrholm, J., Nemes, S., Eriksson, B. I., & Mohaddes, M. (2019) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000714 · Cited by 9
Self-citationAnticoagulation-related nephropathy for the internist: a concise review.
Mezue, K. N., Ram, P., Egbuche, O., Menezes, R. G., Lerma, E. V., & Rangaswami, J. (2020) · PubMed · Cited by 9
Ibrahim, E., Norris, L., & Saadeh, F. A. (2021) · Thrombosis Update · doi:10.1016/j.tru.2021.100038 · Cited by 9
Navas‐Blanco, J. R., Martini, A., & Fabbro, M. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.02.024 · Cited by 9
Bai, C., Ruan, R., Pan, S., Huang, C.-R., Zhang, X., Pang, Y., Zheng, X., & Guo, K. (2021) · Journal of orthopaedic surgery · doi:10.1177/23094990211042674 · Cited by 9
“found that rivaroxaban was significantly more effective in preventing total VTE but was equivalent to enoxaparin regarding the rates of symptomatic VTE and major bleeding complications.(12) However, an increase in wound complication rate and return to surgery was reported in patients who received rivaroxaban after art…”
MethodResultAlfarhan, M. F. A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010107 · Cited by 9
“An e fective blinding procedure was performed by five studies [14,15,18,20,21].”
BackgroundMethodInfluentialClinical Studies with Anticoagulants that Have Changed Clinical Practice
Hirsh, J., de Vries, T. A. C., Eikelboom, J. W., Bhagirath, V. C., & Chan, N. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760330 · Cited by 10
Antithrombotika und Antihämorrhagika
Hein, L. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_15 · Cited by 9
Kwong, L. M. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s26647 · Cited by 9
Rosencher, N., & Albaladejo, P. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.648614 · Cited by 10
“It is worth noting that the post-hoc analysis of European Phase III trials showed no difference in the efficacy of dabigatran etexilate when initial dosing was postponed to the day after surgery [31].”
BackgroundInfluentialPrandoni, P., Temraz, S. N., & Taher, A. T. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.006 · Cited by 9
Rivaroxaban (Xarelto®) : efficacité et tolérance
Rosencher, N., Arnaout, L., Chabbouh, T., & Bellamy, L. (2008) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/s0750-7658(08)75143-8 · Cited by 9
Prevention of Venous Thromboembolism After Surgery
Jaffer, A. K., & Brotman, D. J. (2008) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2008.08.001 · Cited by 10
Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis
Kwong, L. M. (2012) · Orthopedics · doi:10.3928/01477447-20120525-38 · Cited by 9
Anticoagulant Use in Real Time
Srinivasan, D., & Watzak, B. (2012) · Journal of Pharmacy Practice · doi:10.1177/0897190012465950 · Cited by 9
Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
Lessire, S., Dincq, A.-S., Douxfils, J., Devalet, B., Nicolas, J., Anne, S., Larock, A., Jean-Michel, D., Gourdin, M. J., & Mullier, F. (2014) · BioMed Research International · doi:10.1155/2014/616405 · Cited by 12
Drug Interactions with Rivaroxaban following Total Joint Replacement Surgery
Kwong, L. M., & Tong, L. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r055 · Cited by 10
Thankappan, A., Strapps, W. R., DiPietro, M. A., Leander, K. R., Zhang, Z., Shin, M. K., Levorse, J. M., Desai, K., Xu, Y., Lai, K., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0505 · Cited by 9
Pellegrini, V. D. (2015) · JBJS Reviews · doi:10.2106/jbjs.rvw.n.00111 · Cited by 10
Bahloul, M., Regaieg, K., Chtara, K., Turki, O., Baccouch, N., Chaari, A., & Bouaziz, M. (2017) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2016.12.003 · Cited by 10
Vandermeulen, E., Decoster, J., Dewandre, P.-Y., Be, I., Vercauteren, M., & Verhamme, P. B. (2011) · PubMed · Cited by 13
Venous Thromboembolism Prophylaxis after Total Knee Arthroplasty
Box, H., Shahrestani, S. N., & Huo, M. H. (2018) · The Journal of Knee Surgery · doi:10.1055/s-0038-1636907 · Cited by 9
Morais, Q. C. D., & Santos, M. (2020) · Value in Health Regional Issues · doi:10.1016/j.vhri.2020.08.002 · Cited by 12
Khatri, A., Machin, M., Vijay, A., Salim, S., Shalhoub, J., & Davies, A. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194294 · Cited by 10
“The RECORD 1 and RECORD 4 trials compared rivaroxaban to enoxaparin in total hip and knee arthroplasty patients respectively, finding rivaroxaban to be significantly more effective in VTE prevention, with a comparable risk of bleeding [25,26].”
MethodSong, W., Ma, T., Cheng, Q.-Y., Wen, P., Wang, Q., Wu, J., Hao, L., Zhang, B., Wang, Q., & Zhang, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.837163 · Cited by 12
“Some topics burst with long durations, such as VTE and LMWH with a timespan of both 15 years, and rivaroxaban lasting from 2010 until now (23, 35) (Figure 6B).”
BackgroundPerioperative Management of Anticoagulation—Review of Latest Evidence
Kannan, A., Poongkunran, C., Shenoy, S., & Abidov, A. A. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000121 · Cited by 9
Gao, J.-H., Chu, X., Wang, L.-L., Ning, B., & Zhao, C.-X. (2017) · Medicine · doi:10.1097/md.0000000000008059 · Cited by 10
Trivedi, N. N., Fitzgerald, S. J., Schmaier, A. H., & Wera, G. D. (2019) · JBJS Reviews · doi:10.2106/jbjs.rvw.18.00010 · Cited by 10
Rivaroxaban for Prevention and Treatment of Venous Thromboembolism
Chan, N., & Weitz, J. I. (2019) · Future Cardiology · doi:10.2217/fca-2018-0076 · Cited by 12
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes
Romualdi, E., & Ageno, W. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562190 · Cited by 10
“In RECORD 1 [14], patients undergoing THR were randomized to oral rivaroxaban at the dose of 10 mg o.”
BackgroundMethodA NEW METHOD DEVELOPMENT AND VALIDATION FOR ANALYSIS OF RIVAROXABAN IN FORMULATION BY RP HPLC
Dhana, A., Barik, A., & Devanaboyina, N. (2012) · Cited by 12
Pannucci, C. J. (2021) · Aesthetic Surgery Journal · doi:10.1093/asj/sjaa391 · Cited by 9
Prevenção e tratamento do tromboembolismo venoso: o lugar dos novos anticoagulantes orais
Reis, A. (2012) · Revista Portuguesa de Cardiologia · doi:10.1016/s0870-2551(12)70039-2 · Cited by 11
La medicina actual ante los anticoagulantes de nueva generación
Dalmau, F. G.-B. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2011.12.003 · Cited by 10
Shao, J.-B., Cai-fang, N., Duan, P.-F., & Jin, Y.-H. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000438 · Cited by 9
Solms, A., Frede, M., Berkowitz, S. D., Hermanowski‐Vosatka, A., Kubitza, D., Mueck, W., Spiro, T. E., Willmann, S., Yan, X., Zhang, L., et al. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12444 · Cited by 8
Statistical Fragility of Venous Thromboembolism Prophylaxis Following Total Joint Arthroplasty
Sequeira, S. B., Duvall, G. T., & Boucher, H. R. (2023) · Arthroplasty Today · doi:10.1016/j.artd.2023.101111 · Cited by 8
“Most studies evaluating statistical fragility in the adult reconstruction literature have evaluated articles in arthroplasty journals although there are several RCTs in medical journals that have not yet been evaluated for their fragility [11-16].”
BackgroundNew oral therapies for the prevention and treatment of venous thromboembolism
Hellwig, T. R., & Gulseth, M. P. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110601 · Cited by 8
Aspirin for lower limb arthroplasty thromboprophylaxis: review of international guidelines
Donohoe, C. L., Sayana, M. K., Thakral, R., & Niall, D. (2010) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-010-0658-0 · Cited by 8
“In general, the more effective the drug is at lowering VTE rates, the higher the major bleeding risk [1].The bleeding risk with LMWH is approximately 5 and 6% with rivaroxaban and the major bleeding rate is 0.3‐0.7% for rivaroxaban and approximately 0.5% for LMWH [22, 26 , 27].”
BackgroundInfluentialThe changing face of oral anticoagulants
Rider, O. J., & Rider, E. B. (2013) · BDJ · doi:10.1038/sj.bdj.2013.628 · Cited by 8
Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation
Garcia, D. A. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.09.023 · Cited by 8
“[57-60] It is now approved for the primary prevention of VTE following major orthopedic surgery in the US.”
BackgroundNew anticoagulants: Moving on from scientific results to clinical implementation
Eerenberg, E. S., van Es, J., Sijpkens, M. K., Buller, H. R., & Kamphuisen, P. W. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.606829 · Cited by 12
“There was no difference in the occurrence of major bleeding between the rivaroxaban and enoxaparin group (Table II) (32,33).”
BackgroundAhrens, I., & Bode, C. (2012) · Future Cardiology · doi:10.2217/fca.12.26 · Cited by 8
“Rivaroxaban superior to enoxaparin [24]”
Experimental and clinical pharmacology: New oral anticoagulants - clinical applications
Gallus, A. S. (2010) · Australian Prescriber · doi:10.18773/austprescr.2010.018 · Cited by 9
John, M. P., Streufert, B. D., Downes, K. L., Chase, C. B., & Mir, H. R. (2022) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000002454 · Cited by 10
Tyselskyi, V., Tryliskyy, Y., Poylin, V. Y., & Kebkalo, A. (2023) · Polish Journal of Surgery · doi:10.5604/01.3001.0016.2729 · Cited by 8
Yong, B. S. J., Ling, R. R., Ramanathan, K. R., Fan, B. E., Li, R., Poh, J. W., Tan, C. S., Ho, S. W. L., Rochwerg, B. N., & Arya, R. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1787996 · Cited by 10
Neue orale Antikoagulanzien: Konsequenzen für die perioperative Gerinnungsdiagnostik und -therapie
Heindl, B., & Spannagl, M. (2009) · Der Anaesthesist · doi:10.1007/s00101-009-1623-z · Cited by 9
“Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.”
BackgroundInfluentialProphylaxis for venous thromboembolism: guidelines translated for the clinician
Stashenko, G. J., Lópes, R. D., Garcia, D. A., Alexander, J. H., & Tapson, V. F. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0522-0 · Cited by 8
Novel Anticoagulants for Non-valvular Atrial Fibrillation
Xu, B., & Whitbourn, R. (2012) · Heart Lung and Circulation · doi:10.1016/j.hlc.2012.04.002 · Cited by 8
“It has previously been found to be effective in preventing venous thromboembolism following orthopaedic surgery [5].”
BackgroundWarfarin replacements: Mechanisms underlying emerging agents
Turpie, A. G. G. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)71040-7 · Cited by 8
An update on the treatment of malleolar fractures
Driesman, A. S., & Egol, K. A. (2016) · Fuß & Sprunggelenk · doi:10.1016/j.fuspru.2016.02.003 · Cited by 8
Cieri‐Hutcherson, N. E., Kusmierski, K., Lackie, C. L., Opdorp, A. V., & Hassan, A. K. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1888 · Cited by 8
Wang, Z., Zheng, J., Zhao, Y., Xiang, Y., Chen, X., & Jin, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479840 · Cited by 8
Jiang, S., Du, L., & Ni, C. (2017) · International Journal of Pharmacology · doi:10.3923/ijp.2018.1.8 · Cited by 9
Effects of Rivaroxaban on Platelet Aggregation
Hernández‐Juárez, J., Espejo-Godinez, H. G., Mancilla-Padilla, R., Hernández-López, J. R., Alvarado‐Moreno, J. A., Majluf‐Cruz, K., Moreno‐Hernández, M., Isordia‐Salas, I., & Majluf‐Cruz, A. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000770 · Cited by 8
Latest developments in anticoagulant drug discovery
Broussalis, E., Anna, W., Trinka, E., Mutzenbach, J. S., & Killer‐Oberpfalzer, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.011 · Cited by 10
Management of Bleeding Complications in Patients on New Oral Anticoagulants
Gonsalves, W. I., Gupta, V. K., & Patnaik, M. M. (2014) · Cited by 10
Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants
Gao, L., Tadrous, M., Knowles, S. R., Mamdani, M., Paterson, J. M., Juurlink, D. N., & Gomes, T. (2017) · Healthcare policy · doi:10.12927/hcpol.2017.25321 · Cited by 8
“They have also been shown to be superior for prophylaxis of deep vein thrombosis following hip or knee replacement surgeries (Eriksson et al. 2008; Lassen et al. 2010).”
BackgroundInfluentialDeitelzweig, S. B. (2012) · Hospital Practice · doi:10.3810/hp.2012.04.973 · Cited by 8
Henry, B. L., & Desai, U. R. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc182 · Cited by 8
The Evolution of Oral Anticoagulant Therapy
Dittus, C. E., & Ansell, J. (2012) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.011 · Cited by 7
“RECORD-1 and RECORD-2 compared rivaroxaban with enoxaparin, 40 mg daily, starting the night before surgery in patients who received THR (see Table 3).(14,15) In RECORD-1 patients received enoxaparin for 35 days, whereas patients in RECORD-2 received enoxaparin for 10 to 14 days postsurgery.”
BackgroundThromboprophylaxis in Orthopaedic Surgery: A Clinical Review
Rogers, B. A., & Little, N. J. (2010) · Journal of Perioperative Practice · doi:10.1177/175045891002001001 · Cited by 8
Population Pharmacokinetics of Rivaroxaban in Real‐World Patients
Alqahtani, S., Alnahdi, J., Almofada, R., Hazzaa, A. B., Alsultan, A., & Alqahtani, F. H. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2255 · Cited by 7
Volkl, A. A., Moore, K. T., Haskell, L. P., & Barnathan, E. S. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00579-4 · Cited by 7
Salazar, C. A., Basilio-Flores, J. E., Málaga, G., Malasquez, G., & Bernardo, R. J. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011762.pub2 · Cited by 16
Cousin, O., Hello, C. L., & Barrellier, M. ‐. (2011) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2011.04.003 · Cited by 7
Never Events and Related Quality Measures Following Total Hip and Total Knee Replacement
Kwong, L. M. (2010) · Orthopedics · doi:10.3928/01477447-20100924-22 · Cited by 7
The role of novel anticoagulants in the management of venous thromboembolism
Skeik, N., Murphy, C. J., & Porten, B. R. (2014) · Vascular Medicine · doi:10.1177/1358863x14534309 · Cited by 7
Friedman, R. J. (2012) · PubMed Central · Cited by 7
Self-citationEdoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson, C. M., & Finks, S. W. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.048 · Cited by 7
Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
Beyer‐Westendorf, J., Werth, & Halbritter (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s24238 · Cited by 8
A systematic update on the state of novel anticoagulants and a primer on reversal and bridging
Knepper, J. P., Horne, D. C., Andrea, T., & Wakefield, T. W. (2013) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2013.04.006 · Cited by 9
Update on Pharmacologic Therapy for Pulmonary Embolism
Harikrishnan, P., Palaniswamy, C., & Aronow, W. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413506612 · Cited by 9
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.